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BACKGROUND & OBJECTIVE 
Transarterial chemoembolization (TACE) in combination with particles loaded with an anti-angiogenic agent is a promising means for the treatment of 
advanced hepatocellular carcinoma (HCC). Besides depriving the tumor of oxygen and nutrients by embolization of its vessels, the approach provides high 
drug concentration at the tumor site to prevent hypoxia-induced neoangiogenesis and local recurrence [1,2]. 
 
In this context, drug eluting beads (DEBs) were loaded with sunitinib, a multitargeted tyrosine kinase inhibitor. The purpose was to study in vitro the  
loading and release characteristics from differently sized commercially available embolization DC Bead™ microspheres (Biocompatibles, UK) as well as to 
evaluate the pharmacokinetics and tolerance of sunitinib-loaded DEBs in New Zealand white rabbits. 
Katrin Fuchs1, Catherine Siegfried1, Alban Denys3, Pierre Bize3, Olivier Dormond3, Eric Doelker1, Gerrit Borchard1,2 and Olivier Jordan1 
 
1 School of Pharmaceutical Sciences Geneva-Lausanne (EPGL), University of Geneva, CH-1211 Geneva, Switzerland 
2 Centre Pharmapeptides, F-74160 Archamps, France 
3 Unité de Radiologie Interventionnelle, CHUV, University of Lausanne, CH-1011 Lausanne, Switzerland 
 
Sunitinib-loaded microspheres for transarterial 
chemoembolization: in vitro drug release and pharmacokinetic 
profile in rabbits 
 CRS German Chapter, Controlled release systems for proteins and small molecules, 29-30th March 2012, Würzburg, Germany 
 
LOADING CHARACTERISTICS 
Incubation of DC Bead™ in a 10 mg/mL 
sunitinib solution 
Adsorption of sunitinib onto the 
poly(vinyl alcohol) sulfonate moieties 
of the beads due to ionic interactions 
Indirect quantification of drug 
loading by spectrophotometric 
detection (430 nm) 
RELEASE CHARACTERISTICS 
 USP method 4 (flow-through) 
 Sotax CE 6 apparatus (37°C) with 6 
cells, constant-flow CY7 pump (NaCl 
0.9%, 5 ml/min)  
 Spectrophotometric determination 
at 430 nm 
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Fig. 6a Measurements of sunitinib 
levels in the liver 6 hours (n=2) and 
24 hours (n=2) after oral 
administration of 6 mg of sunitinib.  
 
Fig. 4 Release of sunitinib from differently sized beads 
Fig. 1 Drug loading of DC Bead™ particles 
Fig. 2 Ionic interactions between DC Bead™ 
sulfonate residues and sunitinib 
Fig. 5 100-300 µm DC Bead™ before loading (a), after loading (b), after elution in NaCl 0.9% (c) and NaCl 0.9%/EtOH 30% (d)  
PHARMACOKINETIC PROFILES 
High, close to complete and homogeneous drug loading was obtained for both microsphere sizes, 
with a slightly faster loading for the smaller beads ascribed to their higher surface area. 
Almost complete release was detected under physiological conditions, with very similar and fast 
release profiles for 70-150 µm (t50%=0.8 h) and 100-300 µm (t50%=1.5 h) DC Bead™ particles. 
Healthy New Zealand white rabbits received either 0.2 ml of 100-300 
micron sized beads loaded with 6 mg of sunitinib in the hepatic artery 
(n=9) or 6 mg of sunitinib p.o. (n=4). Drug concentrations in plasma and 
liver tissue were assessed by LC MS/MS spectroscopy. 
 
Administration of sunitinib/DC Bead™ caused a significant elevation of 
ALT and AST liver enzymes comparable to the cytolysis expected after 
arterial embolization in the liver. Bilirubin plasmatic levels were not 
affected by the treatment, staying below the detection threshold in all 
measurements.  
Administration of sunitinib p.o. did not cause any alteration of liver 
enzymes. 
 
After embolization drug plasma levels remained low (<50 ng/ml) 
whereas in the liver tissue, very high concentrations at 6 hours (12860 
ng/ml) and 24 hours (9500 ng/ml) were found. 
 
 Fig. 3 Loading of differently sized DC Bead™ particles 
Fig. 6b Measurements of sunitinib 
levels in the liver 6 hours (n=1) and 
24 hours (n=3) after intra-arterial 
administration of 2 ml DC Beads 
loaded with 6 mg of sunitinib  in 
the common hepatic artery.  
 
CONCLUSIONS & OUTLOOK 
REFERENCES 
 DC Bead™ were efficiently and homogeneously loaded with the 
anticancer agent. 
 Release studies showed an elution of the active ingredient in a 
controlled manner from DC Bead™ embolization microspheres of 
different sizes. 
 Sunitinib-eluting beads were well tolerated by rabbits without 
observation of unexpected effects. High liver drug concentration and 
low systemic levels indicated the potential of sunitinib beads for 
hepatocarcinoma treatment. 
 Preliminary animal studies proved antitumoral efficacy of sunitinib-
loaded DC Bead™. Investigations are still under way to define the 
most efficient treatment protocol. 
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